Dr. Daniel G. Baker - 09 Apr 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: CHIEF DEVELOPMENT OFFICER
Issuer ticker: CUE
Reported as of: 09 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Apr 2026, 16:00:03 UTC
Prior SEC filing: 25 Nov 2025
Next SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel G. Baker by Colin Sandercock, attorney-in-fact

Key filing fact

Dr. Daniel G. Baker filed Form 4 for Cue Biopharma, Inc. (CUE) on 10 Apr 2026.

Key facts

This page summarizes Dr. Daniel G. Baker's Form 4 filing for Cue Biopharma, Inc. (CUE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Apr 2026, 16:00.

Change

Previous filing in this sequence was filed on 25 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002046802 Primary reporting owner

Baker Daniel G.

Relationship: CHIEF DEVELOPMENT OFFICER
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Daniel G. Baker by Colin Sandercock, attorney-in-fact
Signature date: 10 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $0.2900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.